HC Wainwright & Co. Maintains Buy on Kezar Life Sciences, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained its Buy rating on Kezar Life Sciences (NASDAQ:KZR) but has lowered the price target from $20 to $7.

July 22, 2024 | 6:21 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
HC Wainwright & Co. has maintained its Buy rating on Kezar Life Sciences but has significantly lowered the price target from $20 to $7.
The maintenance of the Buy rating suggests continued confidence in the company's long-term prospects. However, the significant reduction in the price target from $20 to $7 indicates a reassessment of the company's near-term valuation, likely due to recent performance or market conditions. This mixed signal could lead to short-term downward pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100